Personalized prostate cancer therapy based on systems analysis of the apoptosis regulatory network

Asian J Androl. 2015 May-Jun;17(3):471-4. doi: 10.4103/1008-682X.143749.

Abstract

Targeting the androgen receptor axis provides only temporary relief for advanced prostate cancer, which often evolves into androgen-independent disease. The wide variety of signaling mechanisms connected with the pathophysiology of androgen-independent prostate cancer poses both conceptual and practical challenges for the design of efficient therapies. Analysis of apoptosis regulation in prostate cancer suggests the potential value of a systems approach that integrates information on the topology of the antiapoptotic signaling network, the signal transduction pathways that inhibit apoptosis, and the expression of proteins of the Bcl2 family. This approach could be used to identify patients most likely to respond to treatments with drugs that inhibit the signaling pathways controlling apoptosis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Apoptosis / drug effects
  • Apoptosis / physiology*
  • Humans
  • Male
  • Myeloid Cell Leukemia Sequence 1 Protein / antagonists & inhibitors
  • Myeloid Cell Leukemia Sequence 1 Protein / drug effects
  • Precision Medicine / trends*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / physiopathology
  • Receptors, Androgen / drug effects
  • Receptors, Androgen / physiology
  • Signal Transduction / drug effects
  • Signal Transduction / physiology
  • Systems Analysis*
  • bcl-Associated Death Protein / antagonists & inhibitors
  • bcl-Associated Death Protein / drug effects

Substances

  • AR protein, human
  • Antineoplastic Agents
  • BAD protein, human
  • MCL1 protein, human
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Receptors, Androgen
  • bcl-Associated Death Protein